A new treatment for B-cell acute lymphoblastic leukemia using an antibody-drug conjugate
Official title: A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
Funded at Children's Hospitals and Clinics · NIH-10884330 · Data updated 2026-11-12
This study is testing a new treatment that uses a special drug to help kids and young adults with B-cell acute lymphoblastic leukemia (B-ALL) by targeting cancer cells while trying to keep healthy cells safe, so patients can have a better chance of recovery with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hospitals and Clinics NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | July 7, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $189,780 |
| NIH project number | 5R21CA280433-02 |
| Project ID | NIH-10884330 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include children and young adults diagnosed with B-cell acute lymphoblastic leukemia, particularly those who have experienced relapses.
✕Less likely to help
Patients with other types of leukemia or those who do not have B-cell acute lymphoblastic leukemia may not receive benefit from this research.
What this research studies
This research investigates a novel antibody-drug conjugate targeting the pre-B-cell receptor to treat B-cell acute lymphoblastic leukemia (B-ALL), a common cancer in children and young adults. The approach aims to improve treatment outcomes by addressing the challenges of relapse and complications from current therapies, which often lead to severe immune dysregulation. By focusing on specific B-cell surface markers, the treatment seeks to minimize damage to normal B cells while effectively targeting cancerous cells. Patients may benefit from a safer and more effective treatment option that reduces the risk of infections and other serious side effects.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with B-cell acute lymphoblastic leukemia.
How similar studies have gone: Other research has shown promise in using antibody-drug conjugates for treating various cancers, indicating potential success for this novel approach.
Where this research is happening
-
Children's Hospitals and Clinics
Minneapolis, United States Active
Researchers
- Principal investigator: Winter, Stuart Sheldon — Children's Hospitals and Clinics
- Study coordinator: Winter, Stuart Sheldon
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.